<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
  <title>Origins of Loeys-Dietz Syndrome</title>
  <link rel="website icon" type="image/png" href="./R.jpg">
  <link rel="stylesheet" href="./style.css"/>
</head>
<body>
  <header>
    <div class="logo">Loeys-Dietz Info</div>
    <nav>
      <ul>
        <li><a href="./index.html">Home</a></li>
        <li><a href="./info.html">Information</a></li>
        <li><a href="./about.html">About</a></li>
      </ul>
    </nav>
  </header>

 <main class="timeline-container">
  <h1>Timeline of Loeys-Dietz Syndrome</h1>

  <div class="timeline-single">
    <div class="timeline-entry">
      <span class="date">2005</span>
      <h3>Initial Discovery</h3>
      <p>Drs. Bart Loeys and Hal Dietz first identified Loeys-Dietz syndrome (LDS) as a distinct connective tissue disorder involving mutations in TGFBR1 and TGFBR2.</p>
    </div>

    <div class="timeline-entry">
      <span class="date">2006</span>
      <h3>Types 1 & 2 Classified</h3>
      <p>Type 1 included craniofacial abnormalities and arterial aneurysms. Type 2 lacked craniofacial symptoms but shared vascular characteristics.</p>
    </div>

    <div class="timeline-entry">
      <span class="date">2011</span>
      <h3>Type 3 (SMAD3) Identified</h3>
      <p>Associated with early-onset osteoarthritis and aneurysms. Confirmed autosomal dominant inheritance pattern.</p>
    </div>

    <div class="timeline-entry">
      <span class="date">2012</span>
      <h3>Type 4 (TGFB2) Recognized</h3>
      <p>Found in patients with aortic aneurysms and skeletal features. Helped expand understanding of LDS genetics.</p>
    </div>

    <div class="timeline-entry">
      <span class="date">2015</span>
      <h3>Type 5 (TGFB3) Added</h3>
      <p>Another member of the TGF-beta signaling family. Reinforced the shared pathogenic mechanisms across LDS types.</p>
    </div>

    <div class="timeline-entry">
      <span class="date">2016–2019</span>
      <h3>Type 6 (SMAD2) Discovered</h3>
      <p>Recognized through advanced genome sequencing in atypical LDS cases with overlapping features.</p>
    </div>

    <div class="timeline-entry">
      <span class="date">2020–Present</span>
      <h3>Ongoing Research</h3>
      <p>Focus on targeted therapies for TGF-beta signaling, patient registries, and personalized treatment based on genetic data.</p>
    </div>
  </div>
</main>


  <footer>
    <p>© 2025 Loeys-Dietz Info. All rights reserved.</p>
  </footer>
</body>
</html>
